Ocular art system, sensitivity of 95.5%, specificity of 86.5%, image quality of 97% and satisfies all primary objectives p <0.0001
Los Angeles – (Business Wire / News Wire) April 30, 2019 – Eyenuk, Inc., a vision loss disease estimated to affect 191 million people worldwide by 2030We are announcing today the results of a prospective, multicenter, multi-center clinical trial to validate the EyeArt AI Eye Screening System, which automatically detects diabetic retinopathy (RD).
Ainuq is the world's leading provider of AI technology and services, driving the actual AI Eye Screening ™ application. The results of the study were reviewed by Jennifer Lim (MD, Marion H. Schenk Esq.) At ARVO Imaging at the Eye Conference and a professor and professor at the University of Illinois at Chicago and a retina specialist at Retina Service. ) Director announced.
With the AI Art AI Eye Screening System, doctors can perform real-time DR testing at the hospital so that patients with diabetes who need to consider DR can diagnose them quickly and accurately when they visit the hospital regularly. When the background image of the patient is captured and transmitted to the eye system, the result of the DR scan is recorded in PDF format in 60 seconds. Eye Art System allows ophthalmologists to focus on visual therapy instead of DR.
The main results of this prospective, multicenter and essential clinical trial (NCT03112005) are as follows.
· 942 individuals were enrolled in 15 centers, including primary care, endocrinology, ophthalmology and retina.
· The evaluation of the diaphragmatic background of the AIart AI system is performed by step ETDRSCompared to a comprehensive clinical reference standard consisting of judgments of 4 stereo wide-angle images of Shandong. This classification was handled by the Wisconsin Fundus Photo Reading Center.
Several models of background cameras have been included and evaluated with the AI Art AI Eye Screening System.
· Authorized ophthalmologists (sub-organizations) independently performed the most commonly used DR examination method, the Shandong post-examination.
The test results show that all pre-determined primary endpoint variables were met with p <0.0001. The main results of the main test are as follows (details: http://bit.ly/2GNxugo)
(see pdf, download: http://bit.ly/2GHu6Um)
"This study is significant in that the AI system shows very high accuracy in a very rigorous way compared to the photographic analysis of professional classifiers in the diagnosis of diabetic retinopathy," said Dr. Jennifer Lim, "In this prospective study we demonstrated the validity and availability of this system in testing the likelihood of developing diabetic retinopathy. "This system can help millions of people with diabetes who are at risk of developing diabetic retinopathy have the opportunity to see the risks of loss of vision and gain care with the eyes through tests. "" The high sensitivity and specificity of the ocular art system proves that it is a safe way to identify patients with DR who need DR scanning and visual coordination. "
"The completion of Aiart's traumatic and crucial clinical trials is an important event for Ainuq, and this test shows that Aiat has high sensitivity and diagnostic specificity." We are confident that intelligence has evolved as promised and can have a significant and beneficial impact on the lives of patients around the world. Hundreds of millions of diabetics will soon receive regular and proper eye exams, and many of them can protect the eyes. "
Ainucc will exhibit the AI Art AI Trial System at the ARVO booth at the Vancouver Convention Center 1637.
Overview of EyeArt® AI Eye Screening System
EyeArt AI Screening System The most widely tested AI automatic detection AI technology has tested more than 2 million images in real clinical environments and more than 500,000 patients visiting hospitals around the world. The iAart system was developed with funding from the US National Institutes of Health (NIH) and was accredited by the National Health Service of the United Kingdom (NHS). The iAart system has EU CE Mark and Health Canada licenses. In the United States, it is restricted to use for testing purposes only under federal law.
Video: Diabetic Eye Detection System Eye Art AI Eye Screening (VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy)
Overview of Diabetic Retinopathy (DR)
DR One of the diabetic complications caused by damage to blood vessels in the light sensitive tissue in the retina. It is a silent disease that initially causes no symptoms or causes only a slight visual loss. But, in the end, this can lead to blindness. This disease may develop in patients with type 1 and type 2 diabetes. It is estimated that RD occurs in one third of all diabetics It is becoming one of the leading causes of vision loss at an active age.
Although it is recommended that all diabetics be tested for DR, half of the patients who are actually tested each year The situation is the same in developed countries. In the United States, there are 1,600 diabetic patients by ophthalmologist There is an absolute lack of ophthalmologists who will be in charge of the RD test that diabetic patients need. Patients who receive eye exams every year will also need to wait several weeks or months for a DR appointment in the eye department.
Overview of Eyenuk, Inc.
Eyenuk, Inc., a global provider of AI technology and services, is the world's leading provider of AI Eye Screening ™ for automated disease surveillance in the real world and biomarkers without AI for risk assessment and disease monitoring. IA Predictive Biomarkers ™. The mission of Aninuq is to inspect every eye of the world for the timely diagnosis of life-threatening diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular disease and Alzheimer's disease.
EyeArt is a registered trademark of Eyenuk, Inc.
 International Diabetes Federation. Atlas of Diabetes IDF, Sixth Edition, Brussels, Belgium. 2015.
 Early treatment Photographic risk factors for progressive diabetic retinopathy. ETDRS Report No. 12, 1991, Ophthalmology 98 (5 Suppl): 823-833.
 Yau JW, Rogers SL, Kawasaki R, and others. Overall prevalence and major risk factors for diabetic retinopathy. Diabetes Care. 2012; 35: 556-64. doi: 10.2337 / dc11-1909
 Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a review of the literature. Ophthalmic Research. 2012; 47: 171-188. doi: 10.1159 / 000329603
 http://www.icoph.org/ophthalmologists-worldwide.html and https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Business Wire (businesswire.com) View the original page: https://www.businesswire.com/news/home/20190429005707/en/[이 보도자료는 해당 기업에서 원하는 언어로 작성한 원문을 한국어로 번역한 것이다. 그러므로 번역문의 정확한 사실 확인을 위해서는 원문 대조 절차를 거쳐야 한다. 처음 작성된 원문만이 공식적인 효력을 갖는 발표로 인정되며 모든 법적 책임은 원문에 한해 유효하다.]
Press contact: Eyenuk, Inc. Capwell Communications Ida Yenney +1 949-999-3303[ad_2]